Montagu enters exclusive negotiations with Bridgepoint to acquire HTL Biotechnology Montagu, a leading European private equity firm, has entered into exclusive negotiations with Bridgepoint, to acquire HTL Biotechnology, an international, fast-growing biotech and industrial firm leading the development and production of innovative pharmaceutical grade biopolymers. Financial terms of the transaction are not being disclosed. Founded in 1992, HTL has developed a state-of-the-art biopolymers platform which provides customised, pharmaceutical grade biopolymer solutions to leading pharmaceutical and medical device companies worldwide. Its products are used in therapeutic areas such as ophthalmology, rheumatology, urology, dermatology, and medical aesthetics. The company is recognised as the world pioneer in industrialising the bioproduction of hyaluronic acid. Montagu’s deep sector expertise coupled with the company’s strong healthcare capabilities and organisational foundation will enable HTL to consolidate its global leadership and continue to provide exceptional value to its clients and end-users. “We look forward to partnering with Montagu. Their extensive experience in the healthcare field, will allow us to accelerate our growth, continue to innovate, and realise our international ambitions.” Yvon Bastard, CEO, HTL Biotechnology 123 Yvon Bastard, CEO of HTL, commented, “We look forward to partnering with Montagu. Their extensive experience in the healthcare field will allow us to accelerate our growth, continue to innovate, and realise our international ambitions.” Guillaume Jabalot, Director at Montagu, said: “HTL represents several key features of a Montagu deal, demonstrating a competitive and defensible core business in an attractive market. The management team has accelerated growth and innovation through R&D, which have reinforced the company’s leadership position globally and opened new growth avenues. We are proud to be partnering with HTL and its employees and supporting them in being at the forefront of innovation in the biopolymers sector and improving patients’ lives.” Vincent-Gael Baudet, Partner, Bridgepoint, said: “We’re delighted to have worked with the HTL management team to drive the transition of the company to become a biotechnology platform of scale, and a leading R&D partner to pharmaceutical companies across the world. We wish the management team every success as they embark on the next exciting chapter.” Intech & Coulot join forces to help orthopedic companies leverage the power of additive manufacturing 23rd November 2021 Montagu enters exclusive negotiations with Quilvest Capital Partners to acquire Eudonet Group 3rd November 2021 123456 Privacy Policy Terms & Conditions Regulatory Notices Cookies Modern Slavery Statement Site Map © 2021 Montagu Private Equity LLP